Related Experiment Video
Updated: Jun 24, 2026
12:18
A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
Published on: January 11, 2020
Early intervention for mild cognitive impairment: a randomised controlled trial.
G J Kinsella1, E Mullaly, E Rand
1Psychological Science, La Trobe University, Melbourne, Victoria 3086, Australia. g.kinsella@latrobe.edu.au
Journal of Neurology, Neurosurgery, and Psychiatry
|April 1, 2009
Summary
Cognitive intervention improved everyday memory and strategy use in individuals with amnestic mild cognitive impairment. This early memory rehabilitation helps minimize daily memory failures.
Area of Science:
- Neuroscience
- Cognitive Psychology
- Gerontology
Background:
- Limited research exists on cognitive interventions for mild cognitive impairment (MCI).
- Older adults with MCI experience increasing memory difficulties.
Purpose of the Study:
- To evaluate the effectiveness of early cognitive intervention for memory issues in amnestic MCI.
- To assess the impact of memory rehabilitation on everyday memory and strategy use.
Main Methods:
- Randomized controlled trial with 52 participants diagnosed with amnestic MCI.
- Intervention group received cognitive rehabilitation; control group was waitlisted.
- Assessed prospective memory, memory strategies, and contentment with memory at 2 weeks and 4 months.
Main Results:
- Significant improvements in prospective memory (everyday memory) and knowledge/use of memory strategies.
- No significant change in self-appraised memory or contentment with memory.
- Family partners showed increased knowledge of memory strategies.
Conclusions:
- Cognitive rehabilitation using compensatory strategies is beneficial for individuals with amnestic MCI.
- Early intervention can reduce everyday memory failures and enhance strategy use.
- Further research may explore improving self-appraisal and long-term effects.
Related Concept Videos
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...